ERBB2 and breast carcinoma: In ER-positive HER2-negative breast cancer, a significant correlation was found between a worse prognosis and higher expression of an IFN-correlated metagene, while in patients with HER2-positive breast cancer, a higher expression of the IFN metagene was associated with a better clinical outcome [20].